Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-11-Speech-2-367-125"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20120911.32.2-367-125"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"I support this first reading agreement which will enhance pharmacovigilance within the EU. I particularly favour the introduction of the activation of an automatic urgent procedure allowing the Commission to withdraw from the market a pharmaceutical drug if risks for public safety are detected. I truly believe that more efficient and transparent procedures need to be put in place, especially since the Mediator scandal in France has dramatically highlighted how the lack of uniform and rational rules on this issue can severely harm EU patients’ safety. I particularly commend the fact that the rapporteur has fully understood the importance of ensuring that the highest possible level of protection is equally granted to all EU citizens, also in line with the actual Commission orientation. I also wish to express my full support to this agreement as far as the need for further clarification of transparency obligations on companies when they withdraw a drug is concerned: in the aforementioned Mediator scandal, the French company Servier withdrew Mediator from Spain, claiming it was for commercial reasons, thus severely delaying investigations that might have helped save a number of lives estimated between 500 and 2 000."@en1
|
| lpv:unclassifiedMetadata |
Named graphs describing this resource:
The resource appears as object in 2 triples